Ibandronate for the Prevention of Nonvertebral Fractures: a Pooled Analysis of Individual Patient Data

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2008 Jul 30

PMID 18663402

Citations 31

Authors

A Cranney

G A Wells

E Yetisir

S Adami

C Cooper

P D Delmas

P D Miller

S Papapoulos

J-Y Reginster

P N Sambrook

S Silverman

E Siris

J D Adachi

Affiliations

Soon will be listed here.

Abstract

Unlabelled: This analysis was conducted to assess the effect of high versus lower doses of ibandronate on nonvertebral fractures. The results were adjusted for clinical fracture, age, and bone density. The treatment effect was dose-dependent. Higher doses of ibandronate significantly reduced the risk of nonvertebral fractures more effectively compared with lower doses.

Introduction: The objective of this study was to assess the efficacy of different doses of ibandronate on nonvertebral fractures in a pooled analysis.

Methods: Eight randomized trials of ibandronate were reviewed for inclusion. Alternative definitions of high versus low doses based on annual cumulative exposure (ACE) were explored. A time-to-event analysis was conducted using Kaplan-Meier methodology. Hazard ratios (HR) were derived using Cox regression and adjusted for covariates.

Results: Combining higher ACE doses of > or = 10.8 mg (150 mg once monthly, 3 mg i.v. quarterly, and 2 mg i.v. every 2 months) versus ACE doses of 5.5 mg, from two trials, resulted in an HR 0.62 (95% CI 0.396-0.974, p = 0.038). There was a dose-response trend with increasing ACE doses (7.2-12 mg) versus ACE of 5.5 mg.

Conclusions: A dose-response effect on nonvertebral fractures was observed when comparing high with low ACE doses. A significant reduction in nonvertebral fractures was noted when pooling data from trials using ACE doses of > or = 10.8 mg versus ACE < or = 7.2 mg; and with ACE > or = 10.8 mg versus ACE of 5.5 mg (38% reduction). Higher ibandronate dose levels (150 mg monthly or 3 mg i.v. quarterly) significantly reduced nonvertebral fracture risk in postmenopausal women.

Citing Articles

The effectiveness of ibandronate in reducing the risk of nonvertebral fractures in women with osteoporosis: systematic review and meta-analysis of observational studies.

Alves C, Mendes D, Penedones A, Oliveira T, Donato A, Batel-Marques F Int J Clin Pharm. 2023; 46(2):357-367.

PMID: 38112890 PMC: 10960777. DOI: 10.1007/s11096-023-01666-x.

Healthcare Policy Changes in Osteoporosis Can Improve Outcomes and Reduce Costs in the United States.

Lewiecki E, Ortendahl J, Vanderpuye-Orgle J, Grauer A, Arellano J, Lemay J JBMR Plus. 2019; 3(9):e10192.

PMID: 31667450 PMC: 6808223. DOI: 10.1002/jbm4.10192.

Effectiveness of monthly intravenous ibandronate injections in a real-world setting: Subgroup analysis of a postmarketing observational study.

Takeuchi Y, Hashimoto J, Kakihata H, Nishida Y, Kumagai M, Yamagiwa C Osteoporos Sarcopenia. 2019; 5(1):11-18.

PMID: 31008373 PMC: 6452926. DOI: 10.1016/j.afos.2019.02.002.

Safety and effectiveness of monthly intravenous ibandronate injections in a prospective, postmarketing, and observational study in Japanese patients with osteoporosis.

Takeuchi Y, Hashimoto J, Nishida Y, Yamagiwa C, Tamura T, Atsumi A Osteoporos Sarcopenia. 2019; 4(1):22-28.

PMID: 30775537 PMC: 6362972. DOI: 10.1016/j.afos.2018.01.001.

Combined treatment with minodronate and vitamin C increases bone mineral density and strength in vitamin C-deficient rats.

Segawa T, Miyakoshi N, Kasukawa Y, Aonuma H, Tsuchie H, Shimada Y Osteoporos Sarcopenia. 2019; 2(1):30-37.

PMID: 30775465 PMC: 6372727. DOI: 10.1016/j.afos.2016.01.002.

References

Ravn P, Neugebauer G, Christiansen C . Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Bone. 2002; 30(1):320-4. DOI: 10.1016/s8756-3282(01)00665-2. View

Miller P, McClung M, Macovei L, Stakkestad J, Luckey M, Bonvoisin B . Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005; 20(8):1315-22. DOI: 10.1359/JBMR.050313. View

Thiebaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann J . Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med. 1997; 103(4):298-307. DOI: 10.1016/s0002-9343(97)00249-0. View

Harrington J, Ste-Marie L, Brandi M, Civitelli R, Fardellone P, Grauer A . Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int. 2003; 74(2):129-35. DOI: 10.1007/s00223-003-0042-4. View

Delmas P, Recker R, Chesnut 3rd C, Skag A, Stakkestad J, Emkey R . Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int. 2004; 15(10):792-8. DOI: 10.1007/s00198-004-1602-9. View

Papapoulos S, Quandt S, Liberman U, Hochberg M, Thompson D . Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int. 2004; 16(5):468-74. DOI: 10.1007/s00198-004-1725-z. View

Riis B, Ise J, von Stein T, Bagger Y, Christiansen C . Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res. 2001; 16(10):1871-8. DOI: 10.1359/jbmr.2001.16.10.1871. View

Recker R, Stakkestad J, Chesnut 3rd C, Christiansen C, Skag A, Hoiseth A . Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone. 2004; 34(5):890-9. DOI: 10.1016/j.bone.2004.01.008. View

Delmas P, Adami S, Strugala C, Stakkestad J, Reginster J, Felsenberg D . Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. 2006; 54(6):1838-46. DOI: 10.1002/art.21918. View

10.

Reginster J, Adami S, Lakatos P, Greenwald M, Stepan J, Silverman S . Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2005; 65(5):654-61. PMC: 1798147. DOI: 10.1136/ard.2005.044958. View

11.

Chesnut 3rd C, Skag A, Christiansen C, Recker R, Stakkestad J, Hoiseth A . Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004; 19(8):1241-9. DOI: 10.1359/JBMR.040325. View

12.

Adami S, Felsenberg D, Christiansen C, Robinson J, Lorenc R, Mahoney P . Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone. 2004; 34(5):881-9. DOI: 10.1016/j.bone.2004.01.007. View

13.

Cremers S, Pillai G, Papapoulos S . Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet. 2005; 44(6):551-70. DOI: 10.2165/00003088-200544060-00001. View

14.

Papapoulos S, Schimmer R . Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate. Ann Rheum Dis. 2007; 66(7):853-8. PMC: 1955119. DOI: 10.1136/ard.2006.064931. View

15.

Barrett J, Worth E, Bauss F, Epstein S . Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol. 2004; 44(9):951-65. DOI: 10.1177/0091270004267594. View